73 related articles for article (PubMed ID: 28002792)
1. Extranodal nasal-type NK/T lymphoma treated with chemotherapy and radiotherapy: case series from a European tertiary referral center and review of the literature.
Porte J; Hennequin C; Krizch D; Vercellino L; Guillerm S; Thieblemont C; Quéro L
Strahlenther Onkol; 2024 May; 200(5):434-443. PubMed ID: 37945929
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center.
Yang L; Wei L; Li X; Cong J; Ye J; Yao N; Yang J; Wang L; Wang J
Front Oncol; 2024; 14():1388564. PubMed ID: 38634054
[TBL] [Abstract][Full Text] [Related]
3. A neutrophil/lymphocyte Ratio as a Significant Predictor for Patients with low-risk and early-stage Extranodal NK-T-cell Lymphoma.
Wu W; Chen X; Li N; Luo Q; Zou L
Indian J Hematol Blood Transfus; 2023 Apr; 39(2):228-236. PubMed ID: 37006977
[TBL] [Abstract][Full Text] [Related]
4. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Yamaguchi M; Suzuki R; Oguchi M
Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
[TBL] [Abstract][Full Text] [Related]
5. A retrospective analysis of mature T- and NK-cell lymphomas.
Jia J; Wang X; Song Z; Meng S; Fei Y; Yu J; Liu X; Han X; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Wang X; Zhang H
Cancer Biol Med; 2024 Mar; 21(3):223-9. PubMed ID: 38544483
[No Abstract] [Full Text] [Related]
6. Treatment of extranodal NK/T-cell lymphoma: From past to future.
Yan Z; Yao S; Wang Z; Zhou W; Yao Z; Liu Y
Front Immunol; 2023; 14():1088685. PubMed ID: 36825002
[TBL] [Abstract][Full Text] [Related]
7. Extranodal natural killer/T-cell lymphoma nasal type with extensive ocular tissue involvement: a case report.
Han R; Jiang Y; Bian A; Meng Z; Chen H; Ye J
Diagn Pathol; 2021 Nov; 16(1):104. PubMed ID: 34763717
[TBL] [Abstract][Full Text] [Related]
8. What Effect Does Epstein-Barr Virus Have on Extranodal Natural Killer/T-Cell Lymphoma Prognosis? A Review of 153 Reported Cases.
Tvedten E; Richardson J; Motaparthi K
Cureus; 2021 Sep; 13(9):e17987. PubMed ID: 34540511
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients.
Liu Y; Xue K; Xia Z; Jin J; Wang J; Sun H; Lv F; Liu X; Cao J; Hong X; Guo Y; Ma X; Zhang Q
Cancer Med; 2020 Aug; 9(15):5400-5405. PubMed ID: 32519518
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma.
Cai Q; Cai J; Fang Y; Young KH
Front Oncol; 2019; 9():386. PubMed ID: 31139570
[TBL] [Abstract][Full Text] [Related]
11. [Hemophagocytic lymphohistiocytosis following autologous hematopoietic stem cell transplantation for advanced extranodal NK/T-cell lymphoma: a case report and literatures review].
Yang YQ; He HS; Dai Y; Wei ZL; Liu SH; Yan JW; Huang DP
Zhonghua Xue Ye Xue Za Zhi; 2018 Nov; 39(11):956-959. PubMed ID: 30486597
[No Abstract] [Full Text] [Related]
12. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
[TBL] [Abstract][Full Text] [Related]
13. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
14. Extranodal natural killer/T cell lymphoma: we should and we can do more.
Ying Z; Zhu J
Chin Clin Oncol; 2015 Mar; 4(1):12. PubMed ID: 25841719
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of natural killer-cell malignancies.
Ishida F; Kwong YL
Expert Rev Hematol; 2010 Oct; 3(5):593-602. PubMed ID: 21083476
[TBL] [Abstract][Full Text] [Related]
16. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.
Li YY; Feng LL; Niu SQ; Wang HY; Zhang LL; Wang L; Xia ZJ; Huang HQ; Xia YF; Zhang YJ; Wang XC
Oncotarget; 2017 Feb; 8(7):11480-11488. PubMed ID: 28002792
[TBL] [Abstract][Full Text] [Related]
17. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
